ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis’ Kisqali demonstrates nearly five years median OS in metastatic breast cancer
December 14, 2020Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal ... -
Kisqali Shows Overall Survival Benefit in HR+/HER2- advanced breast cancer
June 02, 2020Kisqali Shows Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer.
Pharma Sources Insight January 2025
